Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

被引：0
作者：
S Mercadante
P Villari
P Ferrera
A Casuccio
S Mangione
G Intravaia
机构：
[1] Pain Relief and Palliative Care Unit,Department of Anesthesia & Intensive Care
[2] La Maddalena Cancer Center,Department of Clinical Neuroscience
[3] Palliative Medicine,undefined
[4] University of Palermo,undefined
[5] University of Palermo,undefined
来源：
British Journal of Cancer | 2007年 / 96卷
关键词：
intravenous morphine; OTFC; breakthrough pain; cancer pain; opioids;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain intensity decreased from a mean of 6.9 to 4.1 and to 2.4 at T1 and T2, respectively. Statistical differences between the two treatments were found at T1 (P=0.013), but not at T2 (P=0.059). Adverse effects were comparable and were not significantly related with the IV-MO and OTFC doses. Intravenous morphine and OTFC in doses proportional to the scheduled daily dose of opioids were both safe and effective, IV-MO having a shorter onset than OTFC. Future comparative studies with appropriate design should compare titration methods and proportional methods of OTFC dosing.
引用
收藏
页码：1828 / 1833
页数：5
相关论文
共 94 条
  • [1] Christie J(1998)Dose–titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 3238-3245
  • [2] Simmonds M(2001)Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR) Pain 91 123-130
  • [3] Patt R(1998)Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 611-616
  • [4] Coluzzi P(2001)Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 149-158
  • [5] Busch MA(2005)The evolving and important role of anesthesiology in palliative care Anesth Analg 100 183-188
  • [6] Nordbrock E(2007)A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials J Palliat Med 10 47-55
  • [7] Portenoy RK(2001)Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 587-593
  • [8] Coluzzi PH(2004)Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, muticentre, dose–titration and long-term use study Palliat Med 18 698-704
  • [9] Schwartzberg L(1999)The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain Anesth Analg 89 732-738
  • [10] Conroy JD(2003)Dose-related respiratory pharmacology of oral transmucosal fentanyl citrate (OTFC) versus intravenous morphine: a randomized, double-blind, double-dummy study Anesthesiology 99 A967-491
12345678910